Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document foreign-private-issuer current reports, shareholder meeting materials and registration statement incorporation for its technology business. Form 6-K reports furnish press releases on AME system orders, commercial deployments, the QTREX platform, cryogenic interconnect development and shareholder communications, while proxy materials cover voting matters such as amendments to the company's articles of association.
Other filings describe governance and officer appointments, ordinary-share voting procedures, Form F-3 and Form S-8 registration statement references, and capital-structure context tied to the company's Nasdaq-listed securities and medical technology operations.
Inspira Technologies OXY B.H.N. Ltd Chief Technology Officer Daniella Yechezkely Hayon reported beneficial ownership of 830,000 ordinary shares as of the reported date. This is an initial ownership filing rather than a new trade.
The position includes restricted stock units: 36,667 RSUs vesting quarterly until February 1, 2027, 100,001 RSUs vesting quarterly until February 1, 2028, 100,000 RSUs vesting on July 1, 2026, 200,000 RSUs vesting quarterly beginning October 1, 2026 until July 1, 2028, and 100,000 RSUs that vest upon achieving specified milestones.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 showing Chief Executive Officer Ben-Noon Dagi Shahar as the beneficial owner of 2,927,239 ordinary shares held directly. This holding includes restricted stock units scheduled to vest quarterly through February 1, 2027 and February 1, 2028.
The filing also reports employee share options covering 57,159 ordinary shares with a converted exercise price of $0.12 per share. These options were granted on November 1, 2020, became fully vested as of January 1, 2021, and are exercisable until April 20, 2030.
Inspira Technologies OXY B.H.N. Ltd reports a 5.2% beneficial ownership stake held by Dagi Ben-Noon. The reporting person beneficially owns 2,297,730 ordinary shares as of 12/31/2025, comprised of 326,739 shares, 1,913,832 RSUs vested or vesting within 60 days, and 57,159 options exercisable within 60 days. The percentage is based on 43,916,997 outstanding ordinary shares.
Inspira Technologies Oxy B.H.N. Ltd. reports two key updates. First, it amended its senior convertible debenture with Bio-View Ltd., extending the deadline to satisfy certain prerequisites from 45 to 75 days and revising the required $5,000,000 investment so it must come from investors introduced under a placement agreement with A.G.P/ Alliance Global Partners.
Second, Inspira received a Nasdaq notice that it is not meeting the minimum market value of publicly held shares requirement of $35,000,000. The company has 180 days, until August 18, 2026, for its market value of publicly held shares to reach at least $35,000,000 for 10 consecutive business days, or its securities may face delisting unless a Nasdaq hearings panel grants relief.
Inspira Technologies is expanding its U.S. presence by deploying its FDA-cleared INSPIRA™ ART100 system at a new premier New York academic medical center ranked among the state’s top 10 hospitals. The system is being integrated into the hospital’s clinical workflow for a structured commercial evaluation.
The evaluation aims to define clinical protocols and assess potential broader institutional adoption, adding to existing commercial activity at other leading U.S. healthcare facilities. Inspira positions the ART100 as a foundation for its next-generation ART500 awake-oxygenation system and is also advancing its HYLA™ continuous blood monitoring platform.
Inspira Technologies Oxy B.H.N. Ltd. entered into a sales agreement allowing at-the-market offerings of its ordinary shares with an aggregate offering price of $2,015,985 through A.G.P./Alliance Global Partners.
The shares are issued under existing Form F-3 registrations and a new prospectus supplement. Inspira plans to use any net proceeds for general corporate purposes, including research and development, regulatory processes, marketing, and commercialization. The company is not obligated to sell any shares, and the sales agent will receive a 3.0% commission on gross proceeds.
Inspira Technologies Oxy B.H.N. Ltd. is offering up to $2,015,985 of ordinary shares through an at-the-market program with A.G.P./Alliance Global Partners under its existing $75 million shelf registration.
The ATM facility lets the company sell shares on Nasdaq from time to time at prevailing prices, paying A.G.P. a 3% commission. Shares outstanding were 43,271,837 as of February 17, 2026, and would rise to 46,694,562 if the full amount were sold at $0.589 per share. The company plans to use net proceeds for research and development, regulatory work, commercialization and general corporate purposes.
The filing highlights substantial dilution for new investors, Nasdaq non-compliance with the $1.00 minimum bid price rule, and an auditor’s going concern paragraph, underscoring financing and listing risks alongside the capital raise.
Inspira Technologies OXY B.H.N. Ltd investor Joe Ronen Hayon has reported his ownership stake in the company. He beneficially owns 3,204,010 ordinary shares, representing 7.3% of the class as of December 31, 2025, based on 43,859,838 shares outstanding.
The holding consists of 655,623 ordinary shares, 2,491,228 ordinary shares from vested restricted stock units, and 57,159 ordinary shares issuable upon options exercisable within 60 days of December 31, 2025. He has sole voting and dispositive power over all 3,204,010 shares and no shared power or group relationships are reported.
Joe Ronen Hayon filed an amended Schedule 13G reporting beneficial ownership of 3,204,010 ordinary shares of Inspira Technologies OXY B.H.N. Ltd, representing 7.3% of the class as of December 31, 2025, based on 43,859,838 outstanding ordinary shares.
The holding consists of 655,623 ordinary shares, 2,491,228 ordinary shares vested from restricted stock units, and 57,159 ordinary shares issuable upon option exercise within 60 days of December 31, 2025. Hayon reports sole voting and dispositive power over all 3,204,010 shares and no shared power.
Inspira Technologies Oxy B.H.N. Ltd. received a Nasdaq notice on February 9, 2026 that its ordinary shares are not in compliance with the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days.
The notice has no immediate effect on trading, and the shares continue on the Nasdaq Capital Market under symbol IINN. The company has 180 days, until August 10, 2026, for its closing bid price to reach at least $1.00 for ten consecutive business days to regain compliance, with the possibility of a second 180‑day period if additional conditions are met.
If compliance is not restored within the allowed period, Nasdaq may delist the shares. Inspira plans to monitor its share price and consider available options, potentially including a reverse share split, to address the deficiency.